Upscaling to large-scale production of Nanologica’s silica started in July 2019. The silica is produced according to Nanologica’s proprietary methods at the contract manufacturer Sterling Pharma Solutions in the UK. The first samples of test material have now been delivered.
” It is very pleasing to having received the first test material from the large-scale production. This shows our production method is scalable and gives us confidence going into ton scale production of product”, says Andreas Bhagwani, CEO Nanologica.
In the second half of 2021, silica product is expected to be delivered from the facilities at Sterling.
For further information, please contact:
Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: firstname.lastname@example.org
About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, and type of porosity of silica particles. This knowledge is applied within drug development and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.